loading
Carisma Therapeutics Inc stock is traded at $0.204, with a volume of 181.58K. It is down -9.73% in the last 24 hours and down -38.18% over the past month. CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
See More
Previous Close:
$0.226
Open:
$0.223
24h Volume:
181.58K
Relative Volume:
0.64
Market Cap:
$7.91M
Revenue:
$20.27M
Net Income/Loss:
$-63.80M
P/E Ratio:
-0.1342
EPS:
-1.52
Net Cash Flow:
$-68.35M
1W Performance:
+7.71%
1M Performance:
-38.18%
6M Performance:
-79.54%
1Y Performance:
-87.56%
1-Day Range:
Value
$0.2015
$0.229
1-Week Range:
Value
$0.1845
$0.2296
52-Week Range:
Value
$0.1601
$1.90

Carisma Therapeutics Inc Stock (CARM) Company Profile

Name
Name
Carisma Therapeutics Inc
Name
Phone
(267) 491-6422
Name
Address
3675 MARKET STREET, PHILADELPHIA
Name
Employee
46
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
CARM's Discussions on Twitter

Compare CARM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CARM
Carisma Therapeutics Inc
0.204 7.91M 20.27M -63.80M -68.35M -1.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-12-24 Downgrade Robert W. Baird Outperform → Neutral
Dec-10-24 Downgrade BTIG Research Buy → Neutral
Apr-11-24 Initiated BTIG Research Buy
Oct-03-23 Initiated CapitalOne Overweight
Jul-06-23 Initiated Evercore ISI Outperform
May-31-23 Upgrade Jefferies Hold → Buy
May-24-23 Initiated H.C. Wainwright Buy
Apr-14-23 Initiated Robert W. Baird Outperform
View All

Carisma Therapeutics Inc Stock (CARM) Latest News

pulisher
Apr 28, 2025

Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace

Apr 28, 2025
pulisher
Apr 23, 2025

Carisma Therapeutics to Present at Upcoming Conferences - Seeking Alpha

Apr 23, 2025
pulisher
Apr 16, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Rating of “Hold” by Analysts - Defense World

Apr 16, 2025
pulisher
Apr 15, 2025

Sagimet Biosciences (NASDAQ:SGMT) and Carisma Therapeutics (NASDAQ:CARM) Head-To-Head Review - Defense World

Apr 15, 2025
pulisher
Apr 08, 2025

Philly weekly roundup: Carisma Therapeutics layoffs; PPA's AI ticketing; HiveBio's first cohort - Technical.ly

Apr 08, 2025
pulisher
Apr 07, 2025

Carisma Therapeutics Inc’s Market Journey: Closing Weak at 0.19, Down -0.26 - DWinneX

Apr 07, 2025
pulisher
Apr 06, 2025

CARISMA THERAPEUTICS Earnings Preview: Recent $CARM Insider Trading, Hedge Fund Activity, and More - Nasdaq

Apr 06, 2025
pulisher
Apr 03, 2025

Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MSN

Apr 03, 2025
pulisher
Apr 02, 2025

Philly’s Carisma Therapeutics slashed its workforce to 6 from 46 for sale or wind down - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Carisma Therapeutics (NASDAQ:CARM) Price Target Lowered to $1.00 at D. Boral Capital - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment - MSN

Apr 01, 2025
pulisher
Apr 01, 2025

Carisma winds down operations, lays off 95% of remaining staff - Fierce Biotech

Apr 01, 2025
pulisher
Mar 31, 2025

Penn spinout Carisma Therapeutics lays off 84% of its staff, explores possible sale - The Business Journals

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Provides Corporate Updates - Citizen Tribune

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 28, 2025

Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st

Mar 28, 2025
pulisher
Mar 28, 2025

Carisma Therapeutics (CARM) to Release Earnings on Monday - Defense World

Mar 28, 2025
pulisher
Mar 22, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World

Mar 22, 2025
pulisher
Mar 19, 2025

Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 19, 2025
pulisher
Mar 13, 2025

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annua - GuruFocus.com

Mar 13, 2025
pulisher
Feb 25, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

Feb 25, 2025
pulisher
Feb 22, 2025

Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference - MSN

Feb 22, 2025
pulisher
Feb 19, 2025

Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 - Quantisnow

Feb 19, 2025
pulisher
Feb 19, 2025

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Quantisnow

Feb 19, 2025
pulisher
Feb 11, 2025

Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference - MSN

Feb 11, 2025
pulisher
Feb 05, 2025

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - Quantisnow

Feb 05, 2025
pulisher
Feb 04, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update - Defense World

Feb 04, 2025
pulisher
Jan 31, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

Jan 30, 2025
pulisher
Jan 29, 2025

Biliary Tract Cancer Market Poised for Significant Growth from - openPR.com

Jan 29, 2025
pulisher
Jan 22, 2025

BTIG Downgrades Carisma Therapeutics (CARM) - MSN

Jan 22, 2025
pulisher
Jan 18, 2025

Evercore ISI Group Downgrades Carisma Therapeutics (CARM) - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

Barclays PLC Has $539,000 Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World

Jan 18, 2025

Carisma Therapeutics Inc Stock (CARM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Cap:     |  Volume (24h):